Indian regulators have escalated action against India's largest drugmaker, Sun Pharma, barring ophthalmic drug production at its Assam factory until it submits a satisfactory compliance report.
India orders top drugmaker to halt eye medicine production at plant over quality lapses
EXECUTIVE SUMMARY
Indian regulators have escalated action against India's largest drugmaker, Sun Pharma, barring ophthalmic drug production at its Assam factory until it submits a satisfactory compliance report.
Key Takeaways
- India orders top drugmaker to halt eye medicine production at plant over quality lapses.
- Indian regulators have escalated action against India's largest drugmaker, Sun Pharma, barring ophthalmic drug production at its Assam factory until it submits a satisfactory compliance report.
- Indian regulators have escalated action against India's largest drugmaker, Sun Pharma, barring ophthalmic drug production at its Assam factory until it submits a satisfactory compliance report.
Read Complete Original Article
Published originally on Channel NewsAsia (CNA) - Feed 6511
